Claro Advisors LLC Buys 164 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Claro Advisors LLC grew its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 25.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 819 shares of the medical equipment provider’s stock after acquiring an additional 164 shares during the period. Claro Advisors LLC’s holdings in Intuitive Surgical were worth $327,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Mutual Advisors LLC grew its holdings in Intuitive Surgical by 27.9% during the 3rd quarter. Mutual Advisors LLC now owns 834 shares of the medical equipment provider’s stock worth $244,000 after acquiring an additional 182 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Intuitive Surgical by 0.8% in the 3rd quarter. AQR Capital Management LLC now owns 80,283 shares of the medical equipment provider’s stock valued at $23,466,000 after acquiring an additional 628 shares during the period. Advisors Asset Management Inc. raised its position in shares of Intuitive Surgical by 2.8% in the 3rd quarter. Advisors Asset Management Inc. now owns 7,649 shares of the medical equipment provider’s stock worth $2,236,000 after acquiring an additional 205 shares in the last quarter. Axxcess Wealth Management LLC lifted its stake in shares of Intuitive Surgical by 531.3% during the 3rd quarter. Axxcess Wealth Management LLC now owns 8,441 shares of the medical equipment provider’s stock worth $2,467,000 after purchasing an additional 7,104 shares during the last quarter. Finally, Alps Advisors Inc. boosted its position in Intuitive Surgical by 28.5% during the third quarter. Alps Advisors Inc. now owns 4,555 shares of the medical equipment provider’s stock valued at $1,331,000 after purchasing an additional 1,010 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ISRG has been the subject of several analyst reports. Stifel Nicolaus increased their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Citigroup upped their price target on Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Jefferies Financial Group increased their price objective on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday, April 19th. The Goldman Sachs Group assumed coverage on Intuitive Surgical in a research note on Thursday, May 30th. They set a “buy” rating and a $500.00 target price on the stock. Finally, Piper Sandler increased their price target on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $403.67.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $436.24 on Tuesday. The firm has a 50-day simple moving average of $403.83 and a two-hundred day simple moving average of $383.50. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $448.10. The company has a market cap of $154.73 billion, a P/E ratio of 78.74, a price-to-earnings-growth ratio of 5.75 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. Intuitive Surgical’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.00 earnings per share. Equities research analysts forecast that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Insider Activity

In related news, EVP Robert Desantis sold 1,498 shares of the business’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $369.92, for a total value of $554,140.16. Following the completion of the sale, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,037,149.44. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Intuitive Surgical news, EVP Myriam Curet sold 5,318 shares of the business’s stock in a transaction on Tuesday, April 23rd. The stock was sold at an average price of $370.66, for a total transaction of $1,971,169.88. Following the transaction, the executive vice president now owns 298 shares of the company’s stock, valued at $110,456.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Robert Desantis sold 1,498 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $369.92, for a total transaction of $554,140.16. Following the transaction, the executive vice president now directly owns 5,507 shares in the company, valued at approximately $2,037,149.44. The disclosure for this sale can be found here. Insiders have sold 17,956 shares of company stock worth $6,927,011 in the last quarter. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.